approval is a guarantee. I'd say reimbursement for rGBM is a guarantee (huge OS improvement and no SoC). Very small risks for reimbursement in certain subtypes for nGBM.
worst case we don't get reimbursement approval for DCVax-L in certain subtypes. Worst case is still great for investors and patients alike.
Market Data 
Markets 
AI
